C-ABL-IN-4

• Description:

  C-ABL-IN-4 is a potent inhibitor of c-Abl. Activation of c-Abl has been implicated in various diseases, notably cancer. c-ABL-IN-4 has the potential for the research of neurodegenerative diseases (amyotrophic lateral sclerosis (ALS) and Parkinson’s disease (PD) and cancer (extracted from patent WO2021048567A1, compound 54) [1].

• UNSPSC:

  12352005

• Target:

  Bcr-Abl

• Type:

  Reference compound

• Related Pathways:

  Protein Tyrosine Kinase/RTK

• Applications:

  Cancer-programmed cell death

• Field of Research:

  Cancer; Neurological Disease

• Assay Protocol:

  https://www.medchemexpress.com/c-abl-in-4.html

• Solubility:

  10 mM in DMSO

• Smiles:

  O=C (C1=CN (C (C=C1) =O) C2=CN=CC (F) =C2) NC3=CC=C (C=C3) OC (F) (Cl) F

• Molecular Formula:

  C18H11ClF3N3O3

• Molecular Weight:

  409.75

• References & Citations:

  [1] Michael J. RAWLING, et al. New compounds and methods. Patent WO2021048567A1.

• Shipping Conditions:

  Room temperature

• Scientific Category:

  Reference compound1

• Clinical Information:

  No Development Reported

• CAS Number:

  2626934-68-5